These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Investment Research • Oct 20, 2026

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas PHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, will present five abstracts from its TIL platform at the European Society for Medical Oncology (ESMO) Congress 2026, including two oral presentations of new clinical data in previously untreated advanced melanoma and, for the first time, in two soft tissue sarcomas. The congress takes place October 23–27, 2026, in Madrid, Spain.

GlobeNewsWire • Oct 19, 2026

Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More

The Undercovered Dozen highlights 12 lesser-covered stocks from the past week on Seeking Alpha. This curated series aims to spark investment ideas and community discussion around overlooked equities. Articles span a range of companies, encouraging investors to explore fresh opportunities beyond mainstream coverage.

Seeking Alpha • Oct 19, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance's common stock to twenty-one new, non-executive employees.

GlobeNewsWire • Oct 16, 2026

Iovance: Buy Now Before Many Growth Catalysts Kick In

Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing losses. I project gross margins reaching 65–70%, although continued cash burn and potential dilution remain risks.

Seeking Alpha • Oct 5, 2026

Top 3 Health Care Stocks That May Collapse In Q4

As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Oct 5, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.

GlobeNewsWire • Oct 1, 2026

Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?

Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trading flat Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.

Benzinga • Sep 30, 2026

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Sep 30, 2026

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026

Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.

Zacks Investment Research • Sep 30, 2026